GODAVARI DRUGS LIMITED

Regd. Off.:'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

To, **Date: 14.08.2026**

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400001

Dear Sir/Madam

Unit: Godavari Drugs Limited (Scrip Code: 530317)

Sub: Outcome of Board Meeting held on 14.08.2026

***

With reference to the subject cited this is to inform the Exchange that the Board of Directors of **Godavari Drugs Limited,** at its Meeting held on Friday, 14th August, 2026, at 11:45 a.m. at the registered office of the Company, considered and approved the following:

1. Un-audited Financial Results for the quarter ended 30.06.2026. **(Attached)**
2. Limited Review Report for the quarter ended 30.06.2026. **(Attached)**
3. Allotment of Equity Shares on conversion of 7,86,690 (Seven Lakhs Eighty-Six Thousand Six Hundred and Ninety Only) warrants into 7,86,690 (Seven Lakhs Eighty-Six Thousand Six Hundred and Ninety Only) Equity Shares at an issue price of Rs. 89/- each (including a premium of Rs. 10/- each), to "Promoters Category", on preferential basis, upon receipt of balance amount aggregating to Rs. 5,25,11,557.5/- (Rupees Five Crores Twenty-Five Lakhs Eleven Thousand Five Hundred and Fifty-Seven and Paise Fifty Only) being 75% of the issue price per warrant, from the allottees pursuant to the exercise of their rights of conversion into equity shares in accordance with the provisions of SEBI (ICDR) Regulations, 2018 and list of allottees as mentioned in below annexures. (Details attached in **Annexure - A**)

Details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as **Annexure-B**.

The meeting concluded at 12.30 p.m.

This is for the information and records of the Exchange, please

Thanking you.

Yours faithfully,
For Godavari Drugs Limited

Achanta Venkatesh

Digitally signed by Achanta Venkatesh
Date: 2026.08.14 12:47:36 +05'30'

Venkatesh Achanta
Company Secretary & Compliance Officer

ANNEXURE - A

List of Proposed Allottees

S No.	Name of the Proposed Allottee	Equity Shares to be Allotted upon conversion of Warrants
Promoter Category		
1.	Ghanshyam Jaju	60,000.00
2.	Kamala Jaju	1,00,000.00
3.	Mohit Jaju	1,33,355.00
4.	Priyanka Jaju	33334
5.	Ieshir Jaju	66667
6.	Mukund Kakani	156334
7.	Sushma Kakani	141000
8.	Tanushree Kakani	46000
9.	Aksheit Kakani	50000
Total		**7,86,690**

ANNEXURE – B

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

S No.	Particulars	Details
1.	**Type of securities proposed to be issued (viz. equity shares, convertibles etc.);**	Equity Shares allotted on conversion of fully paid Warrants.
2.	**Type of Issuance (further public Preferential Allotment offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)**	Preferential allotment, on a private placement basis. (Conversion of Warrants into Equity Shares).
3.	**Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)**	Total number of securities allotted – 7,86,690 Total amount of securities allotted – Rs.5,25,11,557.5/- (7,86,690 number of shares * Rs. 66.75/- paid per share)
4.	**Names of the investors**	As per **Annexure - A**
5.	**Post allotment of securities - outcome of the subscription, issue price / allotted price (in case of convertibles), number of investors**	Post the conversion of warrants into equity shares, the paid-up equity share capital of the Company has increased from Rs. 10,12,74,350/- (Rupees Ten Crores Twelve Lakhs Seventy-Four Thousand Three Hundred and Fifty Only) consisting of 1,01,27,435 (One Crore One Lakhs Twenty-Seven Thousand Four Hundred and Thirty-Five Only) Equity Shares of Rs. 10/- (Rupees Ten Only) each to Rs. 10,91,41,250/- (Rupees Ten Crores Ninety-One Lakhs Forty-One Thousand Two Hundred and Fifty Only) consisting of 1,09,14,125 (One Crore Nine Lakhs Fourteen Thousand One Hundred and Twenty-Five Only) Equity Shares of Rs. 10/- (Rupees Two Only) each. Allotment of 7,86,690 Equity Shares of Face Value of Rs. 10/- each fully paid up upon conversion of Warrants.
6.	**In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument**	Exercise by conversion of 7,86,690 Warrants into 7,86,690 fully paid-up Equity Shares.

GODAVARI DRUGS LIMITED
CIN : L24230TG1987PLC008016
Regd Office : 'Mayfair" S.P.Road, Secunderabad
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

Sl. No.	Particulars					Rupees in Lakhs
			Quarter ended			Year ended
			30.06.2026	31.03.2026	30.06.2025	31.03.2026
			(Unudited)	(Audited)	(Unudited)	(Audited)
1	**Revenue from operations**		2795.72	3316.31	2381.13	10580.81
2	Other Income		15.10	14.12	1.22	80.51
3	**Total Revenue from operations (1+2)**		2810.82	3330.43	2382.35	10661.32
4	**Expenses**					
	(a)	Cost of materials consumed	2614.88	3026.61	1798.93	8888.89
	(b)	Changes in inventories of finished goods & work-in-progress	-634.45	-489.54	-85.41	-1139.13
	(c)	Employee benefits expense	147.68	132.05	135.67	569.66
	(d)	Depreciation & amortization expense	59.28	61.21	60.43	243.21
	(e)	Finance Costs	89.61	95.55	100.46	397.97
	(f)	Other Expenses	416.09	353.17	242.04	1229.93
	Total expenses		2693.09	3179.05	2252.12	10190.53
5	Profit before exceptional Items and tax (3-4)		117.73	151.38	130.23	470.79
6	Exceptional items		-	10.38	-	35.51
7	**Profit before Tax (5+6)**		117.73	161.76	130.23	506.30
8	**Tax expense**		-6.82	-32.68	-26.17	-97.39
9	**Net Profit for the period (7-8)**		110.91	129.08	104.06	408.91
10	**Other Comprehensive Income**					
	(i)	Items that will not be reclassified to profit or loss	-	-	-	-
	(ii)	Income tax relating to Items that will not be reclassified to profit or loss	-	-	-	-
	(iii)	Items that will be reclassified to profit or loss	-	-	-	-
	(iv)	Income tax relating to Items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)		-	-	-	-
11	**Total Comprehensive Income (9+10)**		110.91	129.08	104.06	408.91
12	Paid-up equity share capital (Face Value Rs. 10/- per share)		1012.74	1012.74	753.05	1012.74
13	Other Equity as shown in the Audited Balance Sheet of the previous year		-	6042.04	-	6042.04
14	**Earnings per share**					
	(a)	Basic	1.10	1.71	1.38	5.43
	(b)	Diluted	1.10	1.64	1.38	5.36

1) The above results , as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on August 14, 2026.

2) The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

3) EPS of Current Quarter is based on paid up capital of Rs. 1012.74 Lacs as against Rs. 753.05 Lacs as of 30.06.2025.

4) The format for un-audited quarterly results as prescribed in SEBI's Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5th July, 2016. Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with IND AS.

5) Corresponding figures in previsous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED

Mohit Jaju Digitally signed by Mohit Jaju Date: 2026.08.14 12:48:02 +05'30'

Mohit Jaju
Wholetime Director & CFO
DIN: 03405414

Place: Secunderabad
Date : 14.08.2026

Ayyadevara & Co.
Chartered Accountants

1-2-386/A/1, Gagan Mahal
Hyderabad - 500 029
Ph: +91-40-27632354, 27642952
e-mail: sridevar@yahoo.co.in
URL: www.ayyadevara.com

Independent Auditor's Review Report on unaudited quarterly financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
Godavari Drugs Limited
Secunderabad.

We have reviewed the accompanying statement of unaudited financial results of Godavari Drugs Limited (the Company) for the quarter ended 30th June 2026 (the statement), This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepare policies hance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ayyadevara & Co.,
Chartered Accountants
FRN: 00278S

A Srinivas

Ayyadevara Srinivas
Proprietor
Membership No.028803
Hyderabad , Date: 14/08/2026
UDIN: 26028803PCHIYS8661

AYYADEVARA & CO. CHARTERED ACCOUNTANTS 1-2-386/A/1, Gagan Mahal, Hyd-29.

GODAVARI DRUGS LIMITED

Scrip Code: 530317 | ISIN: INE362C01012

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc.

[Pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

For the quarter ended 30th June, 2026

(Amount in Lakhs)

Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	-
Date of Raising Funds	18-03-2026
Amount Raised	4,411.73
Report filed for Quarter ended	30-06-2026
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	-
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	-
If Yes, Date of shareholder Approval	-
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	Nil
Comments of the auditors, if any	Nil

Objects for which funds have been raised and where there has been a deviation, in the following table:

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Capital Expenditure for the purpose of manufacturing Active Pharmaceutical Ingredients and intermediates, specialty chemicals in various therapeutic categories including Anti HIV and CNS segments as detailed below: a) Civil construction for production blocks, utilities, platforms, supports, foundations for	Not Applicable	11,00.00	0.00	763.27	0.00	-

Plant : A 6/2, MIDC, Nanded - 431 603. Maharashtra, India. E-mail : nnd@godavaridrugs.com
CIN:L24230TG1987PLC008016
GODAVARI DRUGS LIMITED
Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.
Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557
E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
	equipmentsincluding finishing consisting of flooring, painting, etc.; b) Procurement and installation of equipments like reactors, heat exchangers, filtration equipments, dryers, pumps, pipelines and fittings, structural steel, safety equipments, fire fightingequipments, enhancement of capacity and upgradation of effluent treatment facilities, etc.; c) Augmenting the electrical infrastructure right from incoming line from substation to transformer and distribution upto the equipments consisting of transformers, electrical pannels, cables, lighting, earthing, etc. Erection and commissioning of all the above						
2	Working Capital Requirement	Not Applicable	1,711.73	0.00	0.00	0.00	-
3	Repayment of unsecured loans to promoters and / or Directors	Not Applicable	1,600.00	0.00	0.00	0.00	-

Deviation or variation could mean:
(a) Deviation in the objects or purposes for which the funds have been raised or
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

For GODAVARI DRUGS LTD.

GODAVARI DRUGS LTD. SEC'BAD

Managing Director

Signatory Details

Name of signatory	Mukund Kakani
Designation of person	Managing Director
Place	Secunderabad
Date	14-08-2026

GODAVARI DRUGS LIMITED
Regd. Off.:'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.
Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557
E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com
Plant : A 6/2, MIDC, Nanded - 431 603, Maharashtra, India. | E-mail : nnd@godavaridrugs.com
CIN: L24230TG1987PLC008016